Precision medicine approaches are ideally suited for rare tumors where comprehensive characterization may have diagnostic， prognostic， and therapeutic value. We describe the clinical case and molecular characterization of an adolescent with metastatic poorly differentiated carcinoma (PDC). Given the rarity and poor prognosis associated with PDC in children， we utilized genomic analysis and preclinical models to validate oncogenic drivers and identify molecular vulnerabilities.

BRAF，MAX，Patient-derived xenograft (PDX) models，Poorly differentiated carcinoma (PDC)，Precision medicine，Temsirolimus，Whole exome sequencing (WES)，